Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.
Autor: | Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, Gina Jinna Chen, Wei-Xiong Xia, Yi-Sheng Huang, Tian-Sheng Gao, Yi-Min Liu, Ya-Ting Hou, Jian-Fei Li, Jia-Hao Liu, Nian Lu, Chang-Long Chen, Liang-Ru Ke, Hu Liang, Wei-Xin Bei, Wang-Zhong Li, Shu-Hui Dong, Qin Liu, Changqing Xie |
---|---|
Předmět: |
THERAPEUTIC use of antimetabolites
CISPLATIN CANCER relapse RESEARCH funding ANTIMETABOLITES STATISTICAL sampling TREATMENT effectiveness RANDOMIZED controlled trials DESCRIPTIVE statistics TREATMENT duration METASTASIS CANCER chemotherapy DOSE-response relationship in biochemistry GEMCITABINE DRUG efficacy PACLITAXEL NASOPHARYNX cancer COMPARATIVE studies PROGRESSION-free survival CONFIDENCE intervals SURVIVAL analysis (Biometry) EVALUATION |
Zdroj: | BMJ: British Medical Journal; 6/22/2024, Vol. 385 Issue 8433, p1-10, 10p |
Databáze: | Complementary Index |
Externí odkaz: |